APA (7th ed.) Citation

Patnaik, M., Sekeres, M., DeZern, A., Luger, S., Sproat, L., Bejar, R., . . . Padron, E. (2021). 854P Final results of a phase II study of tipifarnib in chronic myelomonocytic leukemia (CMML) and other myelodysplastic/myeloproliferative neoplasms (MDS/MPN). Annals of Oncology, 32, S783. https://doi.org/10.1016/j.annonc.2021.08.147

Chicago Style (17th ed.) Citation

Patnaik, M.M, et al. "854P Final Results of a Phase II Study of Tipifarnib in Chronic Myelomonocytic Leukemia (CMML) and Other Myelodysplastic/myeloproliferative Neoplasms (MDS/MPN)." Annals of Oncology 32 (2021): S783. https://doi.org/10.1016/j.annonc.2021.08.147.

MLA (9th ed.) Citation

Patnaik, M.M, et al. "854P Final Results of a Phase II Study of Tipifarnib in Chronic Myelomonocytic Leukemia (CMML) and Other Myelodysplastic/myeloproliferative Neoplasms (MDS/MPN)." Annals of Oncology, vol. 32, 2021, p. S783, https://doi.org/10.1016/j.annonc.2021.08.147.